ReviewMolecular neurobiology2026
Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence demonstrates that the interplay of amyloidogenesis and tauopathy plays a significant role in exacerbating neurodegeneration in Alzheimer's disease. This interplay of molecular pathways aids in the formation and accumulation of amyloid beta and neurofibrillary tangles extracellularly and intracellularly, respectively. These interconnected pathways highlight the need for the simultaneous inhibition of BACE1 and GSK-3β for the mitigation of disease progression. There are several drugs developed against BACE1 and GSK-3β separately, but they have limited therapeutic efficacy and failed in clinical trials. The failure is due to systemic toxicity and off-target side effects, limited blood-brain barrier permeation, and lower therapeutic benefits. Advances in brain-targeted drug delivery approaches aim to provide site-specific drug delivery, co-delivery of dual drugs, and enhanced stability. Nanoformulations such as lipid-based nanoparticles, polymeric nanoparticles, and hybrid nanoformulations with surface functionalization demonstrate better results in pre-clinical studies. Various research studies have established that targeting amyloidogenesis and tau hyperphosphorylation pathways is a promising therapeutic approach for attenuating neurodegeneration, with the integration of nanotechnology. This review article provides insights into the interplay of BACE1 and GSK-3β molecular signaling pathways, examines the limitations of conventional therapies, and highlights the potential of dual-targeting nanoformulations, while emphasizing the challenges of clinical translation and effective therapeutic strategies to overcome these and treat AD.
Indexed as
Identifiers
42764330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.